Demetrios Braddock, MD, PhD

• Adam Krysztofiak
• Brett Lindenbach
• Clemens Bergwitz
• Diane Krause
• Donald Engelman
• Enrique M. De La Cruz
• Ewa Folta-Stogniew
• Francesc Lopez-Giraldez
• Gauri Panse
• George Tellides
• Gerald I Shulman
• Gianfilippo Coppola
• Hajime Kato
• Jennifer McNiff
• Jonathan Fetene
• Joseph Madri
• Kenneth Hung
• Marie Robert
• Mina Xu
• Patrick Gallagher
• Paul Stabach
• Pengwei Ren
• Peter M. Glazer
• Savanah Gisriel
• Shivani Srivastava
• Stephan Ariyan
• Stephanie Thorn
• Steven Tommasini
• Sudhir Perincheri
• Susan Gueble
• Thomas Carpenter
• Wenxiang Cao

Calcification, Physiologic; Osteoarthropathy, Primary Hypertrophic; Pathology; Pseudoxanthoma Elasticum; Sickle Cell Trait; Rare Diseases; Vascular Calcification

• Catalysis‐Independent ENPP1 Protein Signaling Regulates Mammalian Bone MassZimmerman K, Liu X, von Kroge S, Stabach P, Lester ER, Chu EY, Srivastava S, Somerman MJ, Tommasini SM, Busse B, Schinke T, Carpenter TO, Oheim R, Braddock DT. Catalysis‐Independent ENPP1 Protein Signaling Regulates Mammalian Bone Mass. Journal Of Bone And Mineral Research 2020, 37: 1733-1749. PMID: 35773783, PMCID: PMC9709593, DOI: 10.1002/jbmr.4640.
• Response of enthesopathy in ENPP1 deficiency to enzyme replacement therapy in murine models and enthesopathy comorbidities and quality of life in ENPP1‐deficient adultsAnsh A, Nester C, O'Brien C, Stabach P, Murtada S, Lester E, Khursigara G, Molloy L, Carpenter T, Ferreira C, Braddock D. Response of enthesopathy in ENPP1 deficiency to enzyme replacement therapy in murine models and enthesopathy comorbidities and quality of life in ENPP1‐deficient adults. The FASEB Journal 2022, 36 DOI: 10.1096/fasebj.2022.36.s1.r5311.
• Identification of ENPP1 Haploinsufficiency in Patients With Diffuse Idiopathic Skeletal Hyperostosis and Early‐Onset OsteoporosisKato H, Ansh AJ, Lester ER, Kinoshita Y, Hidaka N, Hoshino Y, Koga M, Taniguchi Y, Uchida T, Yamaguchi H, Niida Y, Nakazato M, Nangaku M, Makita N, Takamura T, Saito T, Braddock DT, Ito N. Identification of ENPP1 Haploinsufficiency in Patients With Diffuse Idiopathic Skeletal Hyperostosis and Early‐Onset Osteoporosis. Journal Of Bone And Mineral Research 2020, 37: 1125-1135. PMID: 35340077, PMCID: PMC9177665, DOI: 10.1002/jbmr.4550.
• ENPP1 in Blood and Bone: Skeletal and Soft Tissue Diseases Induced by ENPP1 DeficiencyFerreira C, Carpenter T, Braddock D. ENPP1 in Blood and Bone: Skeletal and Soft Tissue Diseases Induced by ENPP1 Deficiency. Annual Review Of Pathology Mechanisms Of Disease 2023, 19: 507-540. PMID: 37871131, DOI: 10.1146/annurev-pathmechdis-051222-121126.
• Hypophosphatemic rickets: An unexplained early feature of craniometaphyseal dysplasiaBarros J, Braddock D, Carpenter T. Hypophosphatemic rickets: An unexplained early feature of craniometaphyseal dysplasia. Bone Reports 2023, 19: 101707. PMID: 37654679, PMCID: PMC10466911, DOI: 10.1016/j.bonr.2023.101707.
• Genetics of Diffuse Idiopathic Skeletal Hyperostosis and Ossification of the Spinal LigamentsKato H, Braddock D, Ito N. Genetics of Diffuse Idiopathic Skeletal Hyperostosis and Ossification of the Spinal Ligaments. Current Osteoporosis Reports 2023, 21: 552-566. PMID: 37530996, PMCID: PMC10543536, DOI: 10.1007/s11914-023-00814-6.
• IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expressionTang H, Panse G, Braddock D, Perincheri S, Xu M, McNiff J. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression. Journal Of Cutaneous Pathology 2023, 50: 595-600. PMID: 37082914, DOI: 10.1111/cup.14439.
• Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndromeMurtada S, Mikush N, Wang M, Ren P, Kawamura Y, Ramachandra A, Li D, Braddock D, Tellides G, Gordon L, Humphrey J. Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome. ELife 2023, 12: e82728. PMID: 36930696, PMCID: PMC10023154, DOI: 10.7554/elife.82728.
• Characterization of hearing-impairment in Generalized Arterial Calcification of Infancy (GACI)Theng EH, Brewer CC, Oheim R, Zalewski CK, King KA, Delsmann MM, Rolvien T, Gafni RI, Braddock DT, Jeffrey Kim H, Ferreira CR. Characterization of hearing-impairment in Generalized Arterial Calcification of Infancy (GACI). Orphanet Journal Of Rare Diseases 2022, 17: 273. PMID: 35854274, PMCID: PMC9295326, DOI: 10.1186/s13023-022-02410-w.
• Systematic characterization of enzyme activity on ENPP1 deficiency disease phenotypeAnsh A, Stabach P, Carpenter T, Ferreira C, Braddock D. Systematic characterization of enzyme activity on ENPP1 deficiency disease phenotype. The FASEB Journal 2022, 36 DOI: 10.1096/fasebj.2022.36.s1.r5223.
• Strategies for Glycoengineering Therapeutic ProteinsDammen-Brower K, Epler P, Zhu S, Bernstein ZJ, Stabach PR, Braddock DT, Spangler JB, Yarema KJ. Strategies for Glycoengineering Therapeutic Proteins. Frontiers In Chemistry 2022, 10: 863118. PMID: 35494652, PMCID: PMC9043614, DOI: 10.3389/fchem.2022.863118.
• The cardiomyocyte disrupts pyrimidine biosynthesis in non-myocytes to regulate heart repairLi S, Yokota T, Wang P, Hoeve J, Ma F, Le TM, Abt ER, Zhou Y, Wu R, Nanthavongdouangsy M, Rodriguez A, Wang Y, Lin YJ, Muranaka H, Sharpley M, Braddock DT, MacRae VE, Banerjee U, Chiou PY, Seldin M, Huang D, Teitell M, Gertsman I, Jung M, Bensinger SJ, Damoiseaux R, Faull K, Pellegrini M, Lusis A, Graeber TG, Radu CG, Deb A. The cardiomyocyte disrupts pyrimidine biosynthesis in non-myocytes to regulate heart repair. Journal Of Clinical Investigation 2022, 132: e149711. PMID: 34813507, PMCID: PMC8759793, DOI: 10.1172/jci149711.
• Direct targeting of amplified gene loci for proapoptotic anticancer therapyKaushik Tiwari M, Colon-Rios DA, Tumu HCR, Liu Y, Quijano E, Krysztofiak A, Chan C, Song E, Braddock DT, Suh HW, Saltzman WM, Rogers FA. Direct targeting of amplified gene loci for proapoptotic anticancer therapy. Nature Biotechnology 2021, 40: 325-334. PMID: 34711990, PMCID: PMC8930417, DOI: 10.1038/s41587-021-01057-5.
• Placenta‐derived interferon‐stimulated gene 20 controls ZIKA virus infectionDing J, Aldo P, Roberts CM, Stabach P, Liu H, You Y, Qiu X, Jeong J, Maxwell A, Lindenbach B, Braddock D, Liao A, Mor G. Placenta‐derived interferon‐stimulated gene 20 controls ZIKA virus infection. EMBO Reports 2021, 22: e52450. PMID: 34405956, PMCID: PMC8490983, DOI: 10.15252/embr.202152450.
• Simultaneous colonic T-cell lymphoma and graft-versus-host disease: A rare diagnosisGisriel S, Hung K, Braddock D, Seropian S, Foss F, Robert M, Xu M. Simultaneous colonic T-cell lymphoma and graft-versus-host disease: A rare diagnosis. Human Pathology Reports 2021, 24: 200507. DOI: 10.1016/j.ehpc.2021.200507.
• Musculoskeletal Comorbidities and Quality of Life in ENPP1‐Deficient Adults and the Response of Enthesopathy to Enzyme Replacement Therapy in Murine ModelsFerreira CR, Ansh AJ, Nester C, O'Brien C, Stabach PR, Murtada S, Lester ER, Khursigara G, Molloy L, Carpenter TO, Braddock DT. Musculoskeletal Comorbidities and Quality of Life in ENPP1‐Deficient Adults and the Response of Enthesopathy to Enzyme Replacement Therapy in Murine Models. Journal Of Bone And Mineral Research 2020, 37: 494-504. PMID: 34882836, PMCID: PMC9667476, DOI: 10.1002/jbmr.4487.
• Response of the ENPP1‐Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and MiceFerreira CR, Kavanagh D, Oheim R, Zimmerman K, Stürznickel J, Li X, Stabach P, Rettig RL, Calderone L, MacKichan C, Wang A, Hutchinson HA, Nelson T, Tommasini SM, von Kroge S, Fiedler IA, Lester ER, Moeckel GW, Busse B, Schinke T, Carpenter TO, Levine MA, Horowitz MC, Braddock DT. Response of the ENPP1‐Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and Mice. Journal Of Bone And Mineral Research 2020, 36: 942-955. PMID: 33465815, PMCID: PMC8739051, DOI: 10.1002/jbmr.4254.
• Unraveling the mechanism of recognition of the 3’ splice site of the adenovirus major late promoter intron by the alternative splicing factor PUF60Hsiao HT, Crichlow GV, Murphy JW, Folta-Stogniew EJ, Lolis EJ, Braddock DT. Unraveling the mechanism of recognition of the 3’ splice site of the adenovirus major late promoter intron by the alternative splicing factor PUF60. PLOS ONE 2020, 15: e0242725. PMID: 33253191, PMCID: PMC7703929, DOI: 10.1371/journal.pone.0242725.
• Improving the Pharmacodynamics and In Vivo Activity of ENPP1‐Fc Through Protein and Glycosylation EngineeringStabach PR, Zimmerman K, Adame A, Kavanagh D, Saeui CT, Agatemor C, Gray S, Cao W, De La Cruz EM, Yarema KJ, Braddock DT. Improving the Pharmacodynamics and In Vivo Activity of ENPP1‐Fc Through Protein and Glycosylation Engineering. Clinical And Translational Science 2020, 14: 362-372. PMID: 33064927, PMCID: PMC7877847, DOI: 10.1111/cts.12887.
• ENPP1 regulates bone mass via an unidentified catalytically independent mechanismBraddock D, Zimmerman K, Oheim R, Kroge S, Stabach P, Kavanagh D, Tommasini S, Carpenter T. ENPP1 regulates bone mass via an unidentified catalytically independent mechanism. Bone Reports 2020, 13: 100692. DOI: 10.1016/j.bonr.2020.100692.
• Enpp1 enzyme replacement restores bone mass in murine model of Enpp1 associated osteoporosisBraddock D, Kavanagh D, Oheim R, Zimmerman K, Kroge S, Stabach P, Tommasini S, Levine M, Carpenter T, Horowitz M. Enpp1 enzyme replacement restores bone mass in murine model of Enpp1 associated osteoporosis. Bone Reports 2020, 13: 100623. DOI: 10.1016/j.bonr.2020.100623.
• Genetic pathways disrupted by ENPP1 deficiency provide insight into mechanisms of osteoporosis, osteomalacia, and paradoxical mineralizationMaulding ND, Kavanagh D, Zimmerman K, Coppola G, Carpenter TO, Jue NK, Braddock DT. Genetic pathways disrupted by ENPP1 deficiency provide insight into mechanisms of osteoporosis, osteomalacia, and paradoxical mineralization. Bone 2020, 142: 115656. PMID: 32980560, PMCID: PMC7744330, DOI: 10.1016/j.bone.2020.115656.
• Phylogeny and chemistry of biological mineral transportSchlesinger PH, Braddock DT, Larrouture QC, Ray EC, Riazanski V, Nelson DJ, Tourkova IL, Blair HC. Phylogeny and chemistry of biological mineral transport. Bone 2020, 141: 115621. PMID: 32858255, PMCID: PMC7771281, DOI: 10.1016/j.bone.2020.115621.
• Next generation miRNA inhibition using short anti-seed PNAs encapsulated in PLGA nanoparticlesMalik S, Lim J, Slack FJ, Braddock DT, Bahal R. Next generation miRNA inhibition using short anti-seed PNAs encapsulated in PLGA nanoparticles. Journal Of Controlled Release 2020, 327: 406-419. PMID: 32835710, PMCID: PMC7606596, DOI: 10.1016/j.jconrel.2020.08.026.
• Paradoxical aortic stiffening and subsequent cardiac dysfunction in Hutchinson–Gilford progeria syndromeMurtada SI, Kawamura Y, Caulk AW, Ahmadzadeh H, Mikush N, Zimmerman K, Kavanagh D, Weiss D, Latorre M, Zhuang ZW, Shadel GS, Braddock DT, Humphrey JD. Paradoxical aortic stiffening and subsequent cardiac dysfunction in Hutchinson–Gilford progeria syndrome. Journal Of The Royal Society Interface 2020, 17: 20200066. PMID: 32453981, PMCID: PMC7276555, DOI: 10.1098/rsif.2020.0066.
• Genetic and pharmacologic modulation of cementogenesis via pyrophosphate regulatorsChu EY, Vo TD, Chavez MB, Nagasaki A, Mertz EL, Nociti FH, Aitken SF, Kavanagh D, Zimmerman K, Li X, Stabach PR, Braddock DT, Millán JL, Foster BL, Somerman MJ. Genetic and pharmacologic modulation of cementogenesis via pyrophosphate regulators. Bone 2020, 136: 115329. PMID: 32224162, PMCID: PMC7482720, DOI: 10.1016/j.bone.2020.115329.
• Clinical and Biochemical Phenotypes in a Family With ENPP1 MutationsKotwal A, Ferrer A, Kumar R, Singh RJ, Murthy V, Schultz-Rogers L, Zimmermann M, Lanpher B, Zimmerman K, Stabach PR, Klee E, Braddock DT, Wermers RA. Clinical and Biochemical Phenotypes in a Family With ENPP1 Mutations. Journal Of Bone And Mineral Research 2019, 35: 662-670. PMID: 31826312, PMCID: PMC7771569, DOI: 10.1002/jbmr.3938.
• Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 DeficiencyOheim R, Zimmerman K, Maulding ND, Stürznickel J, von Kroge S, Kavanagh D, Stabach PR, Kornak U, Tommasini SM, Horowitz MC, Amling M, Thompson D, Schinke T, Busse B, Carpenter TO, Braddock DT. Human Heterozygous ENPP1 Deficiency Is Associated With Early Onset Osteoporosis, a Phenotype Recapitulated in a Mouse Model of Enpp1 Deficiency. Journal Of Bone And Mineral Research 2019, 35: 528-539. PMID: 31805212, PMCID: PMC7184798, DOI: 10.1002/jbmr.3911.
• Missense mutations in ENPP1 result in osteoporosis in patients and is recapitulated in the ENPP1 loss of function murine modelBraddock D, Oheim R, Zimmerman K, Kavanagh D, Horowitz M, Carpenter T. Missense mutations in ENPP1 result in osteoporosis in patients and is recapitulated in the ENPP1 loss of function murine model. Bone Abstracts 2019 DOI: 10.1530/boneabs.7.p64.
• Extraskeletal Calcifications in Hutchinson-Gilford Progeria SyndromeGordon C, Cleveland R, Baltrusaitis K, Massaro J, D'Agostino R, Liang M, Snyder B, Walters M, Li X, Braddock D, Kleinman M, Kieran M, Gordon L. Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome. Bone 2019, 125: 103-111. PMID: 31077852, PMCID: PMC6628204, DOI: 10.1016/j.bone.2019.05.008.
• Protein Engineering and Glycan Optimization Improves Pharmicokinetics of an Enzyme Biologic 10‐foldBraddock D, Stabach P, Zimmerman K, Kavanagh D, Sauei C, Yarema K. Protein Engineering and Glycan Optimization Improves Pharmicokinetics of an Enzyme Biologic 10‐fold. The FASEB Journal 2019, 33: 801.1-801.1. DOI: 10.1096/fasebj.2019.33.1_supplement.801.1.
• ENPP1 Enzyme Replacement Prevents the Osteomalacia and Paradoxical Mineralization in the Enpp1asj/asj mouse model of Autosomal Recessive Hypophosphatemic Rickets Type‐2.Braddock D, Kavanagh D, Li X, Carpenter T, Levine M, Horowitz M. ENPP1 Enzyme Replacement Prevents the Osteomalacia and Paradoxical Mineralization in the Enpp1asj/asj mouse model of Autosomal Recessive Hypophosphatemic Rickets Type‐2. The FASEB Journal 2018, 32: 816.13-816.13. DOI: 10.1096/fasebj.2018.32.1_supplement.816.13.
• Anti-tumor Activity of miniPEG-γ-Modified PNAs to Inhibit MicroRNA-210 for Cancer TherapyGupta A, Quijano E, Liu Y, Bahal R, Scanlon SE, Song E, Hsieh WC, Braddock DE, Ly DH, Saltzman WM, Glazer PM. Anti-tumor Activity of miniPEG-γ-Modified PNAs to Inhibit MicroRNA-210 for Cancer Therapy. Molecular Therapy - Nucleic Acids 2017, 9: 111-119. PMID: 29246289, PMCID: PMC5633812, DOI: 10.1016/j.omtn.2017.09.001.
• Intraperitoneal pyrophosphate treatment reduces renal calcifications in Npt2a null miceCaballero D, Li Y, Fetene J, Ponsetto J, Chen A, Zhu C, Braddock DT, Bergwitz C. Intraperitoneal pyrophosphate treatment reduces renal calcifications in Npt2a null mice. PLOS ONE 2017, 12: e0180098. PMID: 28704395, PMCID: PMC5509111, DOI: 10.1371/journal.pone.0180098.
• Novel Biologic Therapy for Untreated Diseases of Vascular CalcificationBraddock D, Kavanagh D, Li X. Novel Biologic Therapy for Untreated Diseases of Vascular Calcification. Blood 2016, 128: 2326. DOI: 10.1182/blood.v128.22.2326.2326.
• In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle deliveryBahal R, Ali McNeer N, Quijano E, Liu Y, Sulkowski P, Turchick A, Lu YC, Bhunia DC, Manna A, Greiner DL, Brehm MA, Cheng CJ, López-Giráldez F, Ricciardi A, Beloor J, Krause DS, Kumar P, Gallagher PG, Braddock DT, Mark Saltzman W, Ly DH, Glazer PM. In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery. Nature Communications 2016, 7: 13304. PMID: 27782131, PMCID: PMC5095181, DOI: 10.1038/ncomms13304.
• ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancyAlbright RA, Stabach P, Cao W, Kavanagh D, Mullen I, Braddock AA, Covo MS, Tehan M, Yang G, Cheng Z, Bouchard K, Yu ZX, Thorn S, Wang X, Folta-Stogniew EJ, Negrete A, Sinusas AJ, Shiloach J, Zubal G, Madri JA, De La Cruz EM, Braddock DT. ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy. Nature Communications 2015, 6: 10006. PMID: 26624227, PMCID: PMC4686714, DOI: 10.1038/ncomms10006.
• pHLIP® Targeting and Delivery of PNA to Silence MicroRNA in Tumor Cells§Engelman D, Cheng C, Bahal R, Babar I, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock D, Glazer P, Saltzman W, Slack F. pHLIP® Targeting and Delivery of PNA to Silence MicroRNA in Tumor Cells§. Biophysical Journal 2015, 108: 552a. DOI: 10.1016/j.bpj.2014.11.3029.
• MicroRNA silencing for cancer therapy targeted to the tumour microenvironmentCheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 2014, 518: 107-110. PMID: 25409146, PMCID: PMC4367962, DOI: 10.1038/nature13905.
• LOP12Broer N, Weichman K, Walker M, Goldberg C, Buonocore S, Braddock D, Lazova R, Narayan D, Ariyan S. LOP12. Plastic & Reconstructive Surgery 2014, 134: 385. DOI: 10.1097/01.prs.0000452842.54374.ca.
• LOP12Broer N, Weichman K, Walker M, Goldberg C, Buonocore S, Braddock D, Lazova R, Narayan D, Ariyan S. LOP12. Plastic & Reconstructive Surgery 2014, 134: 385. DOI: 10.1097/01.prs.0000452929.17222.1b.
• Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenaseMadiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ, Jurczak MJ, Camporez JP, Lee HY, Cline GW, Samuel VT, Kibbey RG, Shulman GI. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014, 510: 542-546. PMID: 24847880, PMCID: PMC4074244, DOI: 10.1038/nature13270.
• Molecular Basis of Purinergic Signal Metabolism by Ectonucleotide Pyrophosphatase/Phosphodiesterases 4 and 1 and Implications in Stroke*♦Albright RA, Ornstein DL, Cao W, Chang WC, Robert D, Tehan M, Hoyer D, Liu L, Stabach P, Yang G, De La Cruz EM, Braddock DT. Molecular Basis of Purinergic Signal Metabolism by Ectonucleotide Pyrophosphatase/Phosphodiesterases 4 and 1 and Implications in Stroke*♦. Journal Of Biological Chemistry 2013, 289: 3294-3306. PMID: 24338010, PMCID: PMC3916532, DOI: 10.1074/jbc.m113.505867.
• Desmoplastic melanoma: A 12-year experience with sentinel lymph node biopsyBroer PN, Walker ME, Goldberg C, Buonocore S, Braddock DT, Lazova R, Narayan D, Ariyan S. Desmoplastic melanoma: A 12-year experience with sentinel lymph node biopsy. European Journal Of Surgical Oncology 2013, 39: 681-685. PMID: 23522951, DOI: 10.1016/j.ejso.2013.02.025.
• NPP4 is a procoagulant enzyme on the surface of vascular endotheliumAlbright RA, Chang WC, Robert D, Ornstein DL, Cao W, Liu L, Redick ME, Young JI, De La Cruz EM, Braddock DT. NPP4 is a procoagulant enzyme on the surface of vascular endothelium. Blood 2012, 120: 4432-4440. PMID: 22995898, PMCID: PMC4017314, DOI: 10.1182/blood-2012-04-425215.
• 119. Desmoplastic melanoma – A 12-year experience with sentinel lymph node biopsyWalker M, Broer P, Goldberg C, Buonocore S, Braddock D, Lazova R, Narayan D, Ariyan S. 119. Desmoplastic melanoma – A 12-year experience with sentinel lymph node biopsy. European Journal Of Surgical Oncology 2012, 38: 771. DOI: 10.1016/j.ejso.2012.06.119.
• Molecular Structure and Biological Activity of NPP-4, An Endothelial Cell Surface Pyrophosphatase/ Phosphodiesterase That Stimulates Platelet Aggregation and Secretion Via Liberation of ADP Upon Hydrolysis of Diadenosine TriphosphateOrnstein D, Albright R, Chang W, Robert D, Cao W, De La Cruz E, Braddock D. Molecular Structure and Biological Activity of NPP-4, An Endothelial Cell Surface Pyrophosphatase/ Phosphodiesterase That Stimulates Platelet Aggregation and Secretion Via Liberation of ADP Upon Hydrolysis of Diadenosine Triphosphate. Blood 2011, 118: 701. DOI: 10.1182/blood.v118.21.701.701.
• Kinetic Analysis of Autotaxin Reveals Substrate-specific Catalytic Pathways and a Mechanism for Lysophosphatidic Acid Distribution*Saunders LP, Cao W, Chang WC, Albright RA, Braddock DT, De La Cruz EM. Kinetic Analysis of Autotaxin Reveals Substrate-specific Catalytic Pathways and a Mechanism for Lysophosphatidic Acid Distribution*. Journal Of Biological Chemistry 2011, 286: 30130-30141. PMID: 21719699, PMCID: PMC3191052, DOI: 10.1074/jbc.m111.246884.
• Autotaxin and lipid signaling pathways as anticancer targets.Braddock DT. Autotaxin and lipid signaling pathways as anticancer targets. Current Opinion In Investigational Drugs 2010, 11: 629-37. PMID: 20496257.
• Quantitative Characterization of the Interactions among c-myc Transcriptional Regulators FUSE, FBP, and FIRHsiao HH, Nath A, Lin CY, Folta-Stogniew EJ, Rhoades E, Braddock DT. Quantitative Characterization of the Interactions among c-myc Transcriptional Regulators FUSE, FBP, and FIR. Biochemistry 2010, 49: 4620-4634. PMID: 20420426, DOI: 10.1021/bi9021445.
• Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasionSaunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, De La Cruz EM, Braddock DT. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Molecular Cancer Therapeutics 2008, 7: 3352-3362. PMID: 18852138, PMCID: PMC7857123, DOI: 10.1158/1535-7163.mct-08-0463.
• Histopathologic and Molecular Aspects of CD56+ Natural Killer/ T-Cell Lymphoma of the TestisOrnstein DL, Bifulco CB, Braddock DT, Howe JG. Histopathologic and Molecular Aspects of CD56+ Natural Killer/ T-Cell Lymphoma of the Testis. International Journal Of Surgical Pathology 2008, 16: 291-300. PMID: 18573785, DOI: 10.1177/1066896907309687.
• Dimerization of FIR upon FUSE DNA binding suggests a mechanism of c‐myc inhibitionCrichlow GV, Zhou H, Hsiao HH, Frederick KB, Debrosse M, Yang Y, Folta-Stogniew EJ, Chung HJ, Fan C, De La Cruz EM, Levens D, Lolis E, Braddock D. Dimerization of FIR upon FUSE DNA binding suggests a mechanism of c‐myc inhibition. The EMBO Journal 2007, 27: 277-289. PMID: 18059478, PMCID: PMC2206118, DOI: 10.1038/sj.emboj.7601936.
• NMR-Driven Discovery of Benzoylanthranilic Acid Inhibitors of Far Upstream Element Binding Protein Binding to the Human Oncogene c-myc PromoterHuth JR, Yu L, Collins I, Mack J, Mendoza R, Isaac B, Braddock DT, Muchmore SW, Comess KM, Fesik SW, Clore GM, Levens D, Hajduk PJ. NMR-Driven Discovery of Benzoylanthranilic Acid Inhibitors of Far Upstream Element Binding Protein Binding to the Human Oncogene c-myc Promoter. Journal Of Medicinal Chemistry 2004, 47: 4851-4857. PMID: 15369388, DOI: 10.1021/jm0497803.
• Molecular basis of sequence‐specific single‐stranded DNA recognition by KH domains: solution structure of a complex between hnRNP K KH3 and single‐stranded DNABraddock DT, Baber JL, Levens D, Clore GM. Molecular basis of sequence‐specific single‐stranded DNA recognition by KH domains: solution structure of a complex between hnRNP K KH3 and single‐stranded DNA. The EMBO Journal 2002, 21: 3476-3485. PMID: 12093748, PMCID: PMC126100, DOI: 10.1093/emboj/cdf352.
• Structure and dynamics of KH domains from FBP bound to single-stranded DNABraddock DT, Louis JM, Baber JL, Levens D, Clore GM. Structure and dynamics of KH domains from FBP bound to single-stranded DNA. Nature 2002, 415: 1051-1056. PMID: 11875576, DOI: 10.1038/4151051a.
• Rapid Identification of Medium- to Large-Scale Interdomain Motion in Modular Proteins Using Dipolar CouplingsBraddock D, Cai M, Baber J, Huang Y, Clore G. Rapid Identification of Medium- to Large-Scale Interdomain Motion in Modular Proteins Using Dipolar Couplings. Journal Of The American Chemical Society 2001, 123: 8634-8635. PMID: 11525687, DOI: 10.1021/ja016234f.
• Biophysical Characterization of gp41 Aggregates Suggests a Model for the Molecular Mechanism of HIV-associated Neurological Damage and Dementia*Caffrey M, Braddock D, Louis J, Abu-Asab M, Kingma D, Liotta L, Tsokos M, Tresser N, Pannell L, Watts N, Steven A, Simon M, Stahl S, Wingfield P, Clore G. Biophysical Characterization of gp41 Aggregates Suggests a Model for the Molecular Mechanism of HIV-associated Neurological Damage and Dementia*. Journal Of Biological Chemistry 2000, 275: 19877-19882. PMID: 10747981, DOI: 10.1074/jbc.m001036200.
• Structure−Function Relationships in Side Chain Lactam Cross-Linked Peptide Models of a Conserved N-Terminal Domain of Apolipoprotein E †Benzinger T, Braddock D, Dominguez S, Burkoth T, Miller-Auer H, Subramanian R, Fless G, Jones D, Lynn D, Meredith S. Structure−Function Relationships in Side Chain Lactam Cross-Linked Peptide Models of a Conserved N-Terminal Domain of Apolipoprotein E †. Biochemistry 1998, 37: 13222-13229. PMID: 9748329, DOI: 10.1021/bi980482f.
• Conformationally Specific Enhancement of Receptor-Mediated LDL Binding and Internalization by Peptide Models of a Conserved Anionic N-Terminal Domain of Human Apolipoprotein E †Braddock D, Mercurius K, Subramanian R, Dominguez S, Davies P, Meredith S. Conformationally Specific Enhancement of Receptor-Mediated LDL Binding and Internalization by Peptide Models of a Conserved Anionic N-Terminal Domain of Human Apolipoprotein E †. Biochemistry 1996, 35: 13975-13984. PMID: 8909295, DOI: 10.1021/bi960006u.
• Structural and thermodynamic characterization of a bioactive peptide model of apolipoprotein E: side-chain lactam bridges to constrain the conformation.Luo P, Braddock D, Subramanian R, Meredith S, Lynn D. Structural and thermodynamic characterization of a bioactive peptide model of apolipoprotein E: side-chain lactam bridges to constrain the conformation. Biochemistry 1994, 33: 12367-77. PMID: 7918459, DOI: 10.1021/bi00207a003.